Analysis of Ginkgo Bioworks' Q3 results and business model, with a focus on growth, customer acquisition and cash flow ...

One of the few bright spots in Boston’s life-science lab space market this year has dimmed.

Return on Assets (ROA): Ginkgo Bioworks Holdings's ROA lags behind industry averages, suggesting challenges in maximizing ...

Ginkgo Bioworks (DNA) delivered earnings and revenue surprises of 55% and 102.77%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Ginkgo Bioworks is headquartered at 27 Drydock Avenue in Boston's Seaport. Ginkgo has canceled its planned move into a ...

Ginkgo Bioworks Holdings, Inc. (DNA) closed at $7.63 in the latest trading session, marking a -1.55% move from the prior day.

Ginkgo Bioworks Holdings, Inc. , which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September ...

In a recent transaction, Steven P. Coen, the Chief Accounting Officer of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA), sold shares of the company's stock, reportedly to cover tax ...

Ginkgo Bioworks Holdings, Inc. (DNA) ended the recent trading session at $8.27, demonstrating a +1.35% swing from the preceding day's closing price. The stock outpaced the S&P 500's daily gain of ...

Investing.com - Ginkgo Bioworks (NYSE: DNA) reported third quarter EPS of $-0.160, $0.07 worse than the analyst estimate of $-0.090. Revenue for the quarter came in at $55.43M... ByInvesting.com ...